Source: Company Data; PL Research

Size: px
Start display at page:

Download "Source: Company Data; PL Research"

Transcription

1 US generics, low RM costs lead to margin surprise May 08, 2014 Surajit Pal Rating Accumulate Price Rs990 Target Price Rs1,156 Implied Upside 16.8% Sensex 22,324 Nifty 6,653 (Prices as on May 07, 2014) Trading data Market Cap. (Rs bn) Shares o/s (m) M Avg. Daily value (Rs m) Major shareholders Promoters 46.75% Foreign 46.75% Domestic Inst % Public & Other 46.75% Stock Performance (%) 1M 6M 12M Absolute Relative How we differ from Consensus EPS (Rs) PL Cons. % Diff Price Performance (RIC: LUPN.BO, BB: LPC IN) (Rs) 1,200 1, May 13 Jul 13 Source: Bloomberg Sep 13 Nov 13 Jan 14 Mar 14 May 14 Sales in line, margins surprising: Lupin s Q4FY14 sales of Rs30.5bn were in line with our expectation, while adjusted EBITDA margin of 26.5% was 300bps ahead of our expectation. Lupin s sales benefitted from changes in product mix in favour of US generics. Shortfall in growth in domestic formulations (2% YoY growth) was substituted with 30% YoY growth in emerging markets (EMs) and 20% YoY growth in API. Together, US generics and EMs have increased contribution of formulation to 81% in Q4FY14 from 78% in Q4FY13. This has partially helped in higher EBITDA margin. New products help in US generic growth: Launches of Niaspan in Mar 14 and Cymbalta and Zymaxid in Nov Dec 13 have helped in 18% YoY growth to US$241m sales in US generics in Q4FY14. Limited competition in Niacin, sole generic in Zymaxid and lower price erosion in Cymbalta have led to higher contribution from new products. However, sales of branded products in US, with 10% contribution to US sales, were disappointing. Loss of patent in Antara, expiration of contracts in Aerochambers and short duation of winter (led to normal flu season) in US led to dismal sales of branded portfolio. Valuation: Maintain Accumulate, increased TP to Rs1,156: While management guided for 25 26% EBITDA margin in FY15, we believe, the major contributor to 26.5% EBITDA was 300bps QoQ reduction in net RM expenses in Q4FY14. Employee expenses increased 3% despite reduction in headcount by 35 reps to current sales force of 125, implying absorption of retrenchment cost in Q4FY14. We expect decrease in employee expenses Q1FY15E onwards. Sales growth is guided at 15 20%, while capex is expected to be US$100m (Rs5bn) and tax rate at 33% in FY15E. We have increased our sales projection by 2% and 4% and EPS by 14% and 12% in FY15E and FY16E, respectively. This has resulted in an increase in our TP to Rs1,156. We, however, continue to maintain Accumulate on the stock. Key financials (Y/e March) E 2016E Revenues (Rs m) 96, , , ,229 Growth (%) EBITDA (Rs m) 22,552 30,028 34,408 38,609 PAT (Rs m) 13,142 18,364 21,810 23,960 EPS (Rs) Growth (%) Net DPS (Rs) Profitability & Valuation E 2016E EBITDA margin (%) RoE (%) RoCE (%) EV / sales (x) EV / EBITDA (x) PE (x) P / BV (x) Net dividend yield (%) Source: Company Data; PL Research Q4FY14 Result Update Prabhudas Lilladher Pvt. Ltd. and/or its associates (the 'Firm') does and/or seeks to do business with companies covered in its research reports. As a result investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of the report. Investors should consider this report as only a single factor in making their investment decision. Please refer to important disclosures and disclaimers at the end of the report

2 Key takeaways from the Analyst Meet With better visibility, management has laid its plan for the company s growth in global exports, especially in the US. Lupin is expected to focus on complex generics and specialty generics to build its portfolio for the US market in the patent cliff era Complex injectables, controlled substance and inhalation drugs to be in focus for complex generic portfolio. Therapeutic areas such as respiratory, dermatology and biosimilars to be the key focus areas for specialty business in US and global exports Key ophthalmic drug Vigamox is expected to be launched in FY15, while Renvela/Renagel is expected to be launched in Lupin plans to develop 12 selective molecules for developing derma portfolio in the next 24 months Ophthalmic business, coupled with specialty business, is to be the focus business likely to expand in Mexico and other LatAm markets. Lupin is actively looking for acquisition in Brazil Management has identified M&A as one of the focus areas for global expansion of its business, including selective entry in the EU Lupin received approval for 22 ANDAs, while launched 20 ANDAs in FY14. It plans to file 20 ANDAs and expects approval for ANDAs in FY15E. The company expects to file ANDA in nasal sprays (accumulate market size US$2bn), DPI and MDI in FY15 17 Japanese generic would continue to be impacted due to third party supply contracts in I rom (signed before acquisition) and depreciation of Yen against Dollar. Management with its JV with Yoshindo (YL Biologic), Lupin expects first biosimilar drug in Japan in 2018 Lupin reduced headcount in the US sales team to 125 from 160 in Q4FY14 due to lack of branded products other than Suprax in the paediatric segment. We expect benefits of lower employee costs from Q1FY15 onwards Domestic business is expected to grow at 20% in FY15, with settlement for higher traders margin. We, however, discounted 15% and 13% YoY in domestic formulations in FY15 and FY16, respectively Higher other income (36% YoY) in Q4FY14 was due to addition of costs (written off previous quarter) and dossier income Guidance for FY15 Sales 15 20%, Capex US$100m (Rs500cr), EBITDA margin to be more than 25% and tax rate remains at 33% May 08,

3 Exhibit 1: Q4FY14 Result Overview (Rs m) Y/e March Q4FY14 Q4FY13 YoY gr. (%) Q3FY14 FY14 FY13 YoY gr. (%) Net Sales 30,516 25, , ,866 94, Raw Material 9,804 9, ,209 38,174 35, % of Net Sales Personnel Cost 3,896 3, ,787 14,647 12, % of Net Sales Others 8,736 6, ,490 30,018 25, % of Net Sales Total Expenditure 22,436 19, ,487 82,838 73, EBITDA 8,080 6, ,343 28,029 20, Margin (%) Depreciation 743 1,290 (42.4) 637 2,610 3,322 (21.4) EBIT 7,337 4, ,706 25,419 17, Other Income ,164 2, Interest (8.1) (35.0) PBT 7,957 5, ,379 28,317 19, Extra Ord. Inc./Exps Total Taxes 2,327 1, ,542 9,622 5, ETR (%) Reported PAT 5,530 4, ,761 18,364 13, Source: Company Data, PL Research May 08,

4 Exhibit 2: Major Sources of Revenues (Rs m) Y/e March Q4FY14 Q4FY13 YoY gr. (%) Q3FY14 FY14 FY13 YoY gr. (%) Domestic market 5,763 5, ,504 24,795 23, % of Sales International market (Exports) 24,752 19, ,326 86,071 70, % of Sales Total 30,515 25, , ,866 94, Formulations 27,601 22, ,857 99,726 85, % of Sales India 5,763 5, ,504 24,795 23, % of Sales International market (Exports) 21,838 17, ,353 74,931 61, % of Sales Advanced Markets (US & EU) 15,494 12, ,228 51,805 40, % of Sales Emerging Markets 3,126 2, ,405 10,171 8, % of Sales Japan 3,218 2, ,720 12,955 13,040 (0.7) % of Sales APIs 2,914 2, ,973 11,140 9, % of Sales Grand Total 30,515 25, , ,866 94, Source: Company Data, PL Research May 08,

5 Income Statement (Rs m) Net Revenue 96, , , ,229 Raw Material Expenses 35,480 38,174 45,045 50,026 Gross Profit 60,785 74,692 86, ,203 Employee Cost 12,488 14,647 17,073 19,680 Other Expenses 25,745 30,018 34,802 41,914 EBITDA 22,552 30,028 34,408 38,609 Depr. & Amortization 3,322 2,610 2,040 3,020 Net Interest Other Income 426 1, Profit before Tax 19,246 28,317 32,552 35,761 Total Tax 5,842 9,622 10,742 11,801 Profit after Tax 13,404 18,695 21,810 23,960 Ex Od items / Min. Int Adj. PAT 13,142 18,364 21,810 23,960 Avg. Shares O/S (m) EPS (Rs.) Cash Flow Abstract (Rs m) C/F from Operations 12,510 9,889 14,312 11,098 C/F from Investing (5,219) (4,593) (7,500) (7,979) C/F from Financing (6,629) (5,404) 5, Inc. / Dec. in Cash 663 (108) 12,218 3,942 Opening Cash 2,447 4,349 7,975 20,193 Closing Cash 3,109 4,241 20,193 24,135 FCFF 5,642 11,811 12,196 8,524 FCFE 896 5,699 17,812 9,582 Key Financial Metrics Growth Revenue (%) EBITDA (%) PAT (%) EPS (%) Profitability EBITDA Margin (%) PAT Margin (%) RoCE (%) RoE (%) Balance Sheet Net Debt : Equity 0.1 (0.1) (0.1) Net Wrkng Cap. (days) Valuation PER (x) P / B (x) EV / EBITDA (x) EV / Sales (x) Earnings Quality Eff. Tax Rate Other Inc / PBT Eff. Depr. Rate (%) FCFE / PAT Source: Company Data, PL Research. Balance Sheet Abstract (Rs m) Shareholder's Funds 52,042 69,316 88, ,891 Total Debt 11,645 5,533 11,149 12,207 Other Liabilities 3,853 4,231 5,286 6,592 Total Liabilities 67,539 79, , ,690 Net Fixed Assets 28,036 30,019 35,478 40,458 Goodwill 5,073 6,579 9,195 12,414 Investments Net Current Assets 30,536 38,733 55,104 69,503 Cash & Equivalents 4,349 7,975 20,193 24,135 Other Current Assets 47,083 53,030 68,390 82,723 Current Liabilities 20,895 22,272 33,478 37,355 Other Assets 3,874 3,730 4,662 6,294 Total Assets 67,539 79, , ,690 Quarterly Financials (Rs m) Y/e March Q1FY14 Q2FY14 Q3FY14 Q4FY14 Net Revenue 24,207 26,315 29,830 30,516 EBITDA 5,340 6,232 7,343 8,080 % of revenue Depr. & Amortization Net Interest Other Income 1,565 1, Profit before Tax 6,226 6,755 7,379 7,957 Total Tax 2,172 2,582 2,542 2,327 Profit after Tax 4,011 4,062 4,761 5,530 Adj. PAT 4,011 4,062 4,761 5,530 Key Operating Metrics India Formulations 24,207 24,795 28,514 32,221 US & EU Formulations 39,739 51,805 63,629 74,658 Japan 13,246 12,955 14,510 15,961 ROW Formulations 8,516 10,171 11,392 13,100 APIs 9,528 11,140 11,658 12,824 Source: Company Data, PL Research. May 08,

6 Prabhudas Lilladher Pvt. Ltd. 3rd Floor, Sadhana House, 570, P. B. Marg, Worli, Mumbai , India Tel: (91 22) Fax: (91 22) Rating Distribution of Research Coverage % of Total Coverage 60% 50% 40% 30% 20% 10% 0% 54.5% 25.0% 19.6% 0.9% BUY Accumulate Reduce Sell PL s Recommendation Nomenclature BUY : Over 15% Outperformance to Sensex over 12 months Accumulate : Outperformance to Sensex over 12 months Reduce : Underperformance to Sensex over 12 months Sell : Over 15% underperformance to Sensex over 12 months Trading Buy : Over 10% absolute upside in 1 month Trading Sell : Over 10% absolute decline in 1 month Not Rated (NR) : No specific call on the stock Under Review (UR) : Rating likely to change shortly This document has been prepared by the Research Division of Prabhudas Lilladher Pvt. Ltd. Mumbai, India (PL) and is meant for use by the recipient only as information and is not for circulation. This document is not to be reported or copied or made available to others without prior permission of PL. It should not be considered or taken as an offer to sell or a solicitation to buy or sell any security. The information contained in this report has been obtained from sources that are considered to be reliable. However, PL has not independently verified the accuracy or completeness of the same. Neither PL nor any of its affiliates, its directors or its employees accept any responsibility of whatsoever nature for the information, statements and opinion given, made available or expressed herein or for any omission therein. Recipients of this report should be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The suitability or otherwise of any investments will depend upon the recipient's particular circumstances and, in case of doubt, advice should be sought from an independent expert/advisor. Either PL or its affiliates or its directors or its employees or its representatives or its clients or their relatives may have position(s), make market, act as principal or engage in transactions of securities of companies referred to in this report and they may have used the research material prior to publication. We may from time to time solicit or perform investment banking or other services for any company mentioned in this document. May 08,

Cig volumes surprise. Source: Company Data; PL Research

Cig volumes surprise. Source: Company Data; PL Research Cig volumes surprise July 26, 2012 Gautam Duggad gautamduggad@plindia.com +91-22-66322233 Rating BUY Price Rs249 Target Price Rs275 Implied Upside 10.4% Sensex 16,640 Nifty 5,043 (Prices as on July 26,

More information

Need to pull up the socks. Source: Company Data; PL Research

Need to pull up the socks. Source: Company Data; PL Research Need to pull up the socks May 11, 2012 Rupa Shah rupashah@plindia.com +91-22-66322244 Rating Accumulate Price Rs148 Target Price Rs162 Implied Upside 9.5% Sensex 16,293 Nifty 4,929 (Prices as on May 11,

More information

Source: Company Data; PL Research

Source: Company Data; PL Research Result disappoints; Competition catching up in key drugs May 14, 2015 Surajit Pal surajitpal@plindia.com +91 22 66322259 Rating Accumulate Price Rs1,632 Target Price Rs1,823 Implied Upside 11.7% Sensex

More information

Bharat Forge. Strong traction in exports. (our estimate Rs730m). Source: Company Data; PL Research

Bharat Forge. Strong traction in exports. (our estimate Rs730m). Source: Company Data; PL Research Strong traction in exports January 24, 2011 Surjit Arora surjitarora@plindia.com +91 22 66322235 Rating Accumulate Price Rs348 Target Price Rs415 Implied Upside 19.3% Sensex 19,008 (Prices as on January

More information

Tata Steel. Source: Company Data; PL Research

Tata Steel. Source: Company Data; PL Research Earnings marred by forex losses and initial start up costs November 12, 2012 Kamlesh Bagmar kamleshbagmar@plindia.com +91-22-66322237 Mandar Dhavle mandardhavle@plindia.com +91-22-66322258 Rating Accumulate

More information

Britannia Industries

Britannia Industries Volumes impacted by slowdown; Margin expands May 27, 2014 Amnish Aggarwal amnishaggarwal@plindia.com +91 22 66322233 Gaurav Jogani gauravjogani@plindia.com +91 22 66322238 Rating BUY Price Rs870 Target

More information

Cadila Healthcare. Source: Company Data; PL Research

Cadila Healthcare. Source: Company Data; PL Research Q4 broadly in line; US remain cornerstone of growth May 26, 2018 Surajit Pal surajitpal@plindia.com +912266322259 Rating Accumulate Price Rs383 Target Price Rs438 Implied Upside 14.4% Sensex 34,925 Nifty

More information

Lupin Result beats expectations; Near term revenue drivers improves grows visibility

Lupin Result beats expectations; Near term revenue drivers improves grows visibility Result beats expectations; Near term revenue drivers improves grows visibility February 10, 2017 Surajit Pal surajitpal@plindia.com +912266322259 Rating Accumulate Price Rs1,495 Target Price Rs1,730 Implied

More information

Pantaloon Retail India

Pantaloon Retail India Sequential moderation in SSS growth May 16, 211 Gautam Duggad gautamduggad@plindia.com +91 22 66322233 Rating BUY Price Rs241 Target Price Rs332 Implied Upside 37.8% Sensex 18,531 (Prices as on May 13,

More information

Thermax. Source: Company Data; PL Research

Thermax. Source: Company Data; PL Research Near term outlook muted, working on building a strong base November 11, 2016 Kunal Sheth kunalsheth@plindia.com +91 22 66322257 Samir Bendre samirbendre@plindia.com +91 22 66322256 Rating Accumulate Price

More information

Cummins India. Growth/margin bottoming. Source: Company Data; PL Research

Cummins India. Growth/margin bottoming. Source: Company Data; PL Research Growth/margin bottoming May 25, 2018 Kunal Sheth kunalsheth@plindia.com +91 22 66322257 Shreyans Jain shreyansjain@plindia.com +91 22 66322256 Rating BUY Price Rs704 Target Price Rs928 Implied Upside 31.8%

More information

Mahindra & Mahindra. Source: Company Data; PL Research

Mahindra & Mahindra. Source: Company Data; PL Research Tractors drive Q2 performance; Accumulate November 11, 2016 Rohan Korde rohankorde@plindia.com +91 22 66322235 Rating Accumulate Price Rs1,242 Target Price Rs1,503 Implied Upside 21.0% Sensex 26,819 Nifty

More information

Maruti Suzuki. Source: Company Data; PL Research

Maruti Suzuki. Source: Company Data; PL Research Run continues, Royalty reduction positive ; Buy January 29, 2018 Saksham Kaushal sakshamkaushal@plindia.com +91 22 66322235 Poorvi Banka poorvibanka@plindia.com +91 22 66322426 Rating BUY Price Rs9,277

More information

TVS Motors. Source: Company Data; PL Research

TVS Motors. Source: Company Data; PL Research Margins trajectory looking up ; Accumulate November 01, 2017 Saksham Kaushal sakshamkaushal@plindia.com +91 22 66322235 Poorvi Banka poorvibanka@plindia.com +91 22 66322426 Rating Accumulate Price Rs709

More information

Bharat Forge. Exports remain subdued, outlook better. Source: Company Data; PL Research

Bharat Forge. Exports remain subdued, outlook better. Source: Company Data; PL Research Exports remain subdued, outlook better November 08, 2016 Rohan Korde rohankorde@plindia.com +91 22 66322235 Rating BUY Price Rs850 Target Price Rs957 Implied Upside 12.6% Sensex 27,591 Nifty 8,544 (Prices

More information

Aurobindo Pharma. Source: Company Data; PL Research

Aurobindo Pharma. Source: Company Data; PL Research Sales miss on few approvals, earnings beats on better revenue May 31, 2016 Surajit Pal surajitpal@plindia.com +912266322259 Rating BUY Price Rs786 Target Price Rs943 Implied Upside 2% Sensex 26,668 Nifty

More information

Apollo Tyres. Profitability likely to improve. Source: Company Data; PL Research

Apollo Tyres. Profitability likely to improve. Source: Company Data; PL Research Profitability likely to improve November 09, 2011 Surjit Arora surjitarora@plindia.com +91-22-66322235 Rating Accumulate Price Rs59 Target Price Rs66 Implied Upside 11.9% Sensex 17,362 (Prices as on November

More information

GMR Infrastructure. Airport revenues on a thaw, Power awaiting its turn. Q3FY13 Result Update

GMR Infrastructure. Airport revenues on a thaw, Power awaiting its turn. Q3FY13 Result Update Airport revenues on a thaw, Power awaiting its turn February 11, 2013 Rupa Shah rupashah@plindia.com +91-22-66322244 Rating Accumulate Price Rs19 Target Price Rs21 Implied Upside 10.5% Sensex 19,461 Nifty

More information

Cadila Healthcare. Source: Company Data; PL Research

Cadila Healthcare. Source: Company Data; PL Research remain tepid; Valuation reflects near term potential May 29, 2017 Surajit Pal surajitpal@plindia.com +912266322259 Rating Accumulate Price Rs444 Target Price Rs460 Implied Upside 3.6% Sensex 31,028 Nifty

More information

Hindustan Zinc. Strong show, H2 to be stronger than H1. Source: Company Data; PL Research

Hindustan Zinc. Strong show, H2 to be stronger than H1. Source: Company Data; PL Research Strong show, H2 to be stronger than H1 October 21, 2014 Kamlesh Bagmar kamleshbagmar@plindia.com +91 22 66322237 Ankit Shah ankitshah@plindia.com +91 22 66322244 Rating BUY Price Rs164 Target Price Rs200

More information

Gujarat State Fertilisers & Chemicals

Gujarat State Fertilisers & Chemicals Capro benzene spreads remain weak; near term muted October 25, 2013 Balwindar Singh balwindarsingh@plindia.com +91-22-66322239 Rating Accumulate Price Rs54 Target Price Rs60 Implied Upside 11.1% Sensex

More information

Siemens. Railways and T&D driving inflows. Source: Company Data; PL Research

Siemens. Railways and T&D driving inflows. Source: Company Data; PL Research Railways and T&D driving inflows November 23, 2016 Kunal Sheth kunalsheth@plindia.com +91 22 66322257 Samir Bendre samirbendre@plindia.com +91 22 66322256 Rating Accumulate Price Rs1,055 Target Price Rs1,230

More information

Crompton Greaves. Looking to exit overseas Power segment! Source: Company Data; PL Research

Crompton Greaves. Looking to exit overseas Power segment! Source: Company Data; PL Research Looking to exit overseas Power segment! May 29, 2015 Kunal Sheth kunalsheth@plindia.com +91 22 66322257 Samir Bendre samirbendre@plindia.com +91 22 66322256 Rating Accumulate Price Rs166 Target Price Rs204

More information

Maruti Suzuki. Source: Company Data; PL Research

Maruti Suzuki. Source: Company Data; PL Research Healthy operating performance; Accumulate October 28, 2016 Rohan Korde rohankorde@plindia.com +91 22 66322235 Rating Accumulate Price Rs5,860 Target Price Rs6,356 Implied Upside 8.5% Sensex 27,916 Nifty

More information

SpiceJet. Healthy operating performance in Q2. Source: Company Data; PL Research

SpiceJet. Healthy operating performance in Q2. Source: Company Data; PL Research Healthy operating performance in Q2 November 28, 2016 Rohan Korde rohankorde@plindia.com +91 22 66322235 Rating BUY Price Rs65 Target Price Rs115 Implied Upside 76.9% Sensex 26,316 Nifty 8,114 (Prices

More information

Cummins India. Source: Company Data; PL Research

Cummins India. Source: Company Data; PL Research Technology leadership, cost optimization key focus October 28, 2016 Kunal Sheth kunalsheth@plindia.com +91 22 66322257 Samir Bendre samirbendre@plindia.com +91 22 66322256 Rating Accumulate Price Rs852

More information

Mphasis. Increased confidence on margins. Source: Company Data; PL Research

Mphasis. Increased confidence on margins. Source: Company Data; PL Research Increased confidence on margins July 25, 2016 Govind Agarwal govindagarwal@plindia.com +91 22 66322300 Rating BUY Price Rs540 Target Price Rs570 Implied Upside 5.6% Sensex 28,095 Nifty 8,636 (Prices as

More information

Cadila Healthcare. Source: Company Data; PL Research

Cadila Healthcare. Source: Company Data; PL Research US, India traction lead Q2 beat; Sustainability to drive valuation November 14, 2017 Surajit Pal surajitpal@plindia.com +912266322259 Rating Accumulate Price Rs449 Target Price Rs519 Implied Upside 15.6%

More information

Dr. Lal PathLabs. Source: Company Data; PL Research

Dr. Lal PathLabs. Source: Company Data; PL Research Operating efficiency, Seasonal tailwind lead growth, margin November 09, 2017 Surajit Pal surajitpal@plindia.com +91 22 66322259 Rating Accumulate Price Rs832 Target Price Rs963 Implied Upside 15.7% Sensex

More information

Glenmark Pharmaceuticals

Glenmark Pharmaceuticals Costcontrol does the wonder, beat est; Consistency required November 03, 2017 Surajit Pal surajitpal@plindia.com +912266322259 Rating Accumulate Price Rs627 Target Price Rs733 Implied Upside 16.9% Sensex

More information

Sun Pharmaceutical Industries

Sun Pharmaceutical Industries Sun acquires Ranbaxy Gain size at a cost of margin premium April 09, 2014 Surajit Pal surajitpal@plindia.com +91 22 66322259 Rating Accumulate Price Rs630 Target Price Rs646 Implied Upside 2.5% Sensex

More information

Source: Company Data; PL Research

Source: Company Data; PL Research Sales beat, headline margins miss on pricing pressure in US August 10, 2016 Surajit Pal surajitpal@plindia.com +912266322259 Rating Reduce Price Rs1,608 Target Price Rs1,419 Implied Upside 11.8% Sensex

More information

Asian Paints. Source: Company Data; PL Research

Asian Paints. Source: Company Data; PL Research Premium valuations to sustain, Accumulate October 4, 17 Amnish Aggarwal amnishaggarwal@plindia.com +91 Gaurav Jogani gauravjogani@plindia.com +91 8 Rating Accumulate Price Rs1,1 Target Price Rs1,9 Implied

More information

Coal India. Source: Company Data; PL Research

Coal India. Source: Company Data; PL Research Realisations drive the beat; E auction to surprise positively in H2 November 13, 2015 Kamlesh Bagmar kamleshbagmar@plindia.com +91 22 66322237 Ankit Shah ankitshah@plindia.com +91 22 66322244 Rating BUY

More information

Aurobindo Pharma. Source: Company Data; PL Research

Aurobindo Pharma. Source: Company Data; PL Research 1QFY17 performance in line; H2FY17 guided to be better August 24, 2016 Surajit Pal surajitpal@plindia.com +912266322259 Rating BUY Price Rs788 Target Price Rs943 Implied Upside 19.7% Sensex 28,060 Nifty

More information

Cadila Healthcare. Source: Company Data; PL Research

Cadila Healthcare. Source: Company Data; PL Research Result is in line; Tall guidance for US, Delivery remains clouded May 15, 2016 Surajit Pal surajitpal@plindia.com +912266322259 Rating Reduce Price Rs327 Target Price Rs338 Implied Upside 3.4% Sensex 25,490

More information

Asian Paints. Source: Company Data; PL Research

Asian Paints. Source: Company Data; PL Research Premium Valuations to sustain, Accumulate May, 17 Amnish Aggarwal amnishaggarwal@plindia.com +91 Gaurav Jogani gauravjogani@plindia.com +91 8 Rating Accumulate Price Rs1,18 Target Price Rs1,171 Implied

More information

Allcargo Logistics. Source: Company Data; PL Research

Allcargo Logistics. Source: Company Data; PL Research Slow capex continue to impact PES, weak show continues May 24, 2018 Keyur Pandya keyurpandya@plindia.com +912266322247 R Sreesankar rsreesankar@plindia.com +912266322214 Rating Accumulate Price Rs120 Target

More information

Dr. Reddy's Laboratories

Dr. Reddy's Laboratories New US generics, India sales to counter price erosion in FY17 May 12, 2016 Surajit Pal surajitpal@plindia.com +912266322259 Rating Accumulate Price Rs2,971 Target Price Rs2,993 Implied Upside.7% Sensex

More information

Eicher Motors. Continues to ride high! Accumulate. Source: Company Data; PL Research

Eicher Motors. Continues to ride high! Accumulate. Source: Company Data; PL Research Continues to ride high! Accumulate November 14, 2017 Saksham Kaushal sakshamkaushal@plindia.com +91 22 66322235 Poorvi Banka poorvibanka@plindia.com +91 22 66322426 Rating Accumulate Price Rs30,083 Target

More information

Coal India. Source: Company Data; PL Research

Coal India. Source: Company Data; PL Research Earnings marred by weak realisations; Downgrade to Accumulate September 14, 2016 Kamlesh Bagmar kamleshbagmar@plindia.com +91 22 66322237 Ankit Shah ankitshah@plindia.com +91 22 66322244 Rating Accumulate

More information

Bharat Petroleum Corporation

Bharat Petroleum Corporation Higher inventory loss drag earnings August 14, 2017 Avishek Datta avishekdatta@plindia.com +91 22 66322254 Rating BUY Price Rs479 Target Price Rs553 Implied Upside 15.4% Sensex 31,449 Nifty 9,794 (Prices

More information

Aurobindo Pharma. Source: Company Data; PL Research

Aurobindo Pharma. Source: Company Data; PL Research US injectable, OTC, EU geared for higher growth in FY19E February 09, 2018 Surajit Pal surajitpal@plindia.com +912266322259 Rating BUY Price Rs602 Target Price Rs909 Implied Upside 51.0% Sensex 34,413

More information

Coal India. Source: Company Data; PL Research

Coal India. Source: Company Data; PL Research Misses estimates; Higher costs dims hope for earnings recovery February 13, 2017 Kamlesh Bagmar kamleshbagmar@plindia.com +91 22 66322237 Rating Reduce Price Rs325 Target Price Rs320 Implied Upside 1.5%

More information

Dr. Reddy's Laboratories

Dr. Reddy's Laboratories PSAI, India saves the day; US generics to face more October 25, 2016 Surajit Pal surajitpal@plindia.com +912266322259 Rating Reduce Price Rs3,200 Target Price Rs2,945 Implied Upside 8.0% Sensex 28,091

More information

Cadila Healthcare. Source: Company Data; PL Research

Cadila Healthcare. Source: Company Data; PL Research Sales marginally better, EBITDA disappoints February 08, 2016 Surajit Pal surajitpal@plindia.com +912266322259 Rating Reduce Price Rs326 Target Price Rs338 Implied Upside 3.7% Sensex 24,617 Nifty 7,489

More information

Hindalco Industries. Source: Company Data; PL Research

Hindalco Industries. Source: Company Data; PL Research Beats its own best; building up for next leg of growth May 08, 2018 Kamlesh Bagmar kamleshbagmar@plindia.com +91 22 66322237 Amit Khimesra amitkhimesra@plindia.com +91 22 66322244 Rating BUY Price Rs239

More information

Source: Company Data; PL Research

Source: Company Data; PL Research Strong inflow growth, renewable/railways key drivers October 28, 2016 Kunal Sheth kunalsheth@plindia.com +91 22 66322257 Samir Bendre samirbendre@plindia.com +91 22 66322256 Rating Accumulate Price Rs1,063

More information

Britannia Industries

Britannia Industries Sustains momentum; Input cost gains peaked out November 09, 2015 Amnish Aggarwal amnishaggarwal@plindia.com +91 22 66322233 Gaurav Jogani gauravjogani@plindia.com +91 22 66322238 Rating Accumulate Price

More information

Maruti Suzuki. In a league of its own ; Buy. Source: Company Data; PL Research

Maruti Suzuki. In a league of its own ; Buy. Source: Company Data; PL Research In a league of its own ; Buy October 28, 2017 Saksham Kaushal sakshamkaushal@plindia.com +91 22 66322235 Poorvi Banka poorvibanka@plindia.com +91 22 66322426 Rating BUY Price Rs8,115 Target Price Rs9,250

More information

Jindal Steel & Power

Jindal Steel & Power Good show in tough environment; well placed for long term BUY May 05, 2016 Kamlesh Bagmar kamleshbagmar@plindia.com +91 22 66322237 Ankit Shah ankitshah@plindia.com +91 22 66322244 Rating Accumulate Price

More information

Persistent Systems. Growth led by Enterprise Retain BUY. Source: Company Data; PL Research

Persistent Systems. Growth led by Enterprise Retain BUY. Source: Company Data; PL Research Growth led by Enterprise Retain BUY October 26, 20 Govind Agarwal govindagarwal@plindia.com +91 22 66322300 Hussain Kagzi hussainkagzi@plindia.com +91 22 66322242 Rating BUY Price Rs669 Target Price Rs780

More information

Glenmark Pharmaceuticals

Glenmark Pharmaceuticals Sales beat, Oneoff play spoilsport with headline margins May 15, 2016 Surajit Pal surajitpal@plindia.com +912266322259 Rating BUY Price Rs869 Target Price Rs1,186 Implied Upside 36.5% Sensex 25,490 Nifty

More information

Crompton Greaves Consumer Electricals

Crompton Greaves Consumer Electricals Building strong base for growth May 16, 2018 Kunal Sheth kunalsheth@plindia.com +91 22 66322257 Shreyans Jain shreyansjain@plindia.com +91 22 66322256 Rating BUY Price Rs228 Target Price Rs299 Implied

More information

JK Lakshmi Cement. Source: Company Data; PL Research

JK Lakshmi Cement. Source: Company Data; PL Research Expansions on schedule; lower costs to aid margins June 28, 2016 Kamlesh Bagmar kamleshbagmar@plindia.com +91 22 66322237 Ankit Shah ankitshah@plindia.com +91 22 66322244 Rating BUY Price Rs385 Target

More information

Coal India. Source: Company Data; PL Research

Coal India. Source: Company Data; PL Research Lower costs and higher scale off sets weaker realisations February 12, 2016 Kamlesh Bagmar kamleshbagmar@plindia.com +91 22 66322237 Ankit Shah ankitshah@plindia.com +91 22 66322244 Rating BUY Price Rs305

More information

Cadila Healthcare. Source: Company Data; PL Research

Cadila Healthcare. Source: Company Data; PL Research Overall performance disappoints, headwinds continue October 26, 2016 Surajit Pal surajitpal@plindia.com +912266322259 Rating Reduce Price Rs388 Target Price Rs337 Implied Upside 13.1% Sensex 27,837 Nifty

More information

Glenmark Pharmaceuticals

Glenmark Pharmaceuticals Mupirocin: Glenmark to monopoly post FDA s WL to GSK July 22, 2016 Surajit Pal surajitpal@plindia.com +91 22 66322259 Rating BUY Price Rs865 Target Price Rs1,186 Implied Upside 37.1% Sensex 27,803 Nifty

More information

NIIT Technologies. Strong growth in core services. Source: Company Data; PL Research

NIIT Technologies. Strong growth in core services. Source: Company Data; PL Research Strong growth in core services October 19, 2015 Govind Agarwal govindagarwal@plindia.com +91 22 66322300 Hussain Kagzi hussainkagzi@plindia.com +91 22 66322242 Rating BUY Price Rs494 Target Price Rs625

More information

Larsen & Toubro. Decent performance! Source: Company Data; PL Research

Larsen & Toubro. Decent performance! Source: Company Data; PL Research Decent performance! July 30, 2016 Kunal Sheth kunalsheth@plindia.com +91 22 66322257 Samir Bendre samirbendre@plindia.com +91 22 66322256 Rating BUY Price Rs1,558 Target Price Rs1,590 Implied Upside 2.1%

More information

Source: Company Data; PL Research

Source: Company Data; PL Research Soft performance; Organization restructuring on the cards January 21, 2011 Shashi Bhusan shashibhusan@plindia.com +91 22 66322300 Rating Accumulate Price Rs456 Target Price Rs550 Implied Upside 20.6% Sensex

More information

Ashok Leyland. Source: Company Data; PL Research

Ashok Leyland. Source: Company Data; PL Research Short term headwinds, structural story intact; Accumulate November 09, 2017 Saksham Kaushal sakshamkaushal@plindia.com +91 22 66322235 Poorvi Banka poorvibanka@plindia.com +91 22 66322426 Rating Accumulate

More information

Hindustan Zinc. Source: Company Data; PL Research

Hindustan Zinc. Source: Company Data; PL Research Beat on all counts; tight supplies to keep the Zinc prices firm October 20, 2015 Kamlesh Bagmar kamleshbagmar@plindia.com +91 22 66322237 Ankit Shah ankitshah@plindia.com +91 22 66322244 Rating BUY Price

More information

Tata Motors. Source: Company Data; PL Research

Tata Motors. Source: Company Data; PL Research Good show...but tread carefully ; Accumulate November 09, 2017 Saksham Kaushal sakshamkaushal@plindia.com +91 22 66322235 Poorvi Banka poorvibanka@plindia.com +91 22 66322426 Rating Accumulate Price Rs440

More information

Navneet Education. ILL loss hurts consolidated earnings growth. Source: Company Data; PL Research

Navneet Education. ILL loss hurts consolidated earnings growth. Source: Company Data; PL Research ILL loss hurts consolidated earnings growth May 14, 2018 Keyur Pandya keyurpandya@plindia.com +91 22 66322247 R Sreesankar rsreesankar@plindia.com +91 22 66322214 Rating Accumulate Price Rs140 Target Price

More information

Larsen & Toubro. Revenues a positive surprise...so is other income! Q1FY13 Result Update

Larsen & Toubro. Revenues a positive surprise...so is other income! Q1FY13 Result Update Revenues a positive surprise...so is other income! July 23, 2012 Rupa Shah rupashah@plindia.com +91-22-66322244 Rating Accumulate Price Rs1,378 Target Price Rs1,517 Implied Upside 10.1% Sensex 16,877 Nifty

More information

Indraprastha Gas. Growth traction continues. Source: Company Data; PL Research

Indraprastha Gas. Growth traction continues. Source: Company Data; PL Research Growth traction continues June 28, 216 Avishek Datta avishekdatta@plindia.com +91 22 66322254 Rating BUY Price Rs65 Target Price Rs632 Implied Upside 4.5% Sensex 26,43 Nifty 8,95 (Prices as on June 27,

More information

Eicher Motors. Source: Company Data; PL Research

Eicher Motors. Source: Company Data; PL Research Good show continues; In line quarter! Accumulate May 09, 2018 Saksham Kaushal sakshamkaushal@plindia.com +91 22 66322235 Poorvi Banka poorvibanka@plindia.com +91 22 66322426 Rating Accumulate Price Rs30,305

More information

Bharat Electronics. Best defence play. Source: Company Data; PL Research

Bharat Electronics. Best defence play. Source: Company Data; PL Research Best defence play October 31, 2017 Kunal Sheth kunalsheth@plindia.com +91 22 66322257 Shreyans Jain shreyansjain@plindia.com +91 22 66322256 Rating BUY Price Rs185 Target Price Rs219 Implied Upside 18.4%

More information

Reliance Industries. Impressive performance. Source: Company Data; PL Research

Reliance Industries. Impressive performance. Source: Company Data; PL Research Impressive performance April 25, 2017 Avishek Datta avishekdatta@plindia.com +91 22 66322254 Rating Accumulate Price Rs1,416 Target Price Rs1,343 Implied Upside 5.2% Sensex 29,656 Nifty 9,218 (Prices as

More information

Hindustan Zinc. Source: Company Data; PL Research

Hindustan Zinc. Source: Company Data; PL Research Earnings in line; best placed in the base metal pack July 21, 2016 Kamlesh Bagmar kamleshbagmar@plindia.com +91 22 66322237 Ankit Shah ankitshah@plindia.com +91 22 66322244 Rating Accumulate Price Rs193

More information

Aurobindo Pharma. Source: Company Data; PL Research

Aurobindo Pharma. Source: Company Data; PL Research Babystep in US OTC Diversifying patent cliff uncertainty November 13, 2014 Surajit Pal surajitpal@plindia.com +91 22 66322259 Rating BUY Price Rs1,062 Target Price Rs1,308 Implied Upside 23.2% Sensex 28,009

More information

Tata Motors. Source: Company Data; PL Research

Tata Motors. Source: Company Data; PL Research JLR margin disappoints, Standalone turning around; Accumulate February 06, 2018 Saksham Kaushal sakshamkaushal@plindia.com +91 22 66322235 Poorvi Banka poorvibanka@plindia.com +91 22 66322426 Rating Accumulate

More information

Hindustan Unilever. In the Pink of Health ; Accumulate. Source: Company Data; PL Research

Hindustan Unilever. In the Pink of Health ; Accumulate. Source: Company Data; PL Research In the Pink of Health ; Accumulate May 14, 2018 Amnish Aggarwal amnishaggarwal@plindia.com +91 22 66322233 Nishita Doshi nishitadoshi@plindia.com +91 22 66322381 Rating Accumulate Price Rs1,505 Target

More information

Mphasis. Source: Company Data; PL Research

Mphasis. Source: Company Data; PL Research Setting path for growth in Direct Channel, Retain Accumulate June 18, 2015 Shashi Bhusan shashibhusan@plindia.com +91 22 66322300 Hussain Kagzi hussainkagzi@plindia.com +91 22 66322242 Rating Accumulate

More information

Colgate Palmolive. Source: Company Data; PL Research

Colgate Palmolive. Source: Company Data; PL Research 6 8% EPS cut as competitive threat looms large May 24, 2016 Amnish Aggarwal amnishaggarwal@plindia.com +91 22 66322233 Gaurav Jogani gauravjogani@plindia.com +91 22 66322238 Rating Accumulate Price Rs835

More information

Ultratech Cement. Source: Company Data; PL Research

Ultratech Cement. Source: Company Data; PL Research Higher realisations drove the show; Price led recovery still away April 25, 2018 Kamlesh Bagmar kamleshbagmar@plindia.com +91 22 66322237 Amit Khimesra amitkhimesra@plindia.com +91 22 66322244 Rating Accumulate

More information

Tech Mahindra. Source: Company Data; PL Research

Tech Mahindra. Source: Company Data; PL Research Margin beat driven by Headcount reduction November 01, 2017 Madhu Babu madhubabu@plindia.com +91 22 66322300 Rating BUY Price Rs489 Target Price Rs535 Implied Upside 9.4% Sensex 33,600 Nifty 10,441 (Prices

More information

Bharat Forge. Growth on all fronts; Accumulate. Source: Company Data; PL Research

Bharat Forge. Growth on all fronts; Accumulate. Source: Company Data; PL Research Growth on all fronts; Accumulate November 08, 2017 Saksham Kaushal sakshamkaushal@plindia.com +91 22 66322235 Poorvi Banka poorvibanka@plindia.com +91 22 66322426 Rating Accumulate Price Rs728 Target Price

More information

Va Tech Wabag. On track for a strong H2FY16. Source: Company Data; PL Research

Va Tech Wabag. On track for a strong H2FY16. Source: Company Data; PL Research On track for a strong H2FY16 November 09, 2015 Nishna Biyani nishnabiyani@plindia.com +91 22 66322239 Keyur Pandya keyurpandya@plindia.com +91 22 +91 22 66322247 Rating BUY Price Rs668 Target Price Rs1,000

More information

Larsen & Toubro. Source: Company Data; PL Research

Larsen & Toubro. Source: Company Data; PL Research Domestic execution showing positive trends July 28, 2017 Kunal Sheth kunalsheth@plindia.com +91 22 66322257 Rating BUY Price Rs1,159 Target Price Rs1,328 Implied Upside 14.6% Sensex 32,310 Nifty 10,015

More information

Source: Company Data; PL Research

Source: Company Data; PL Research Valuations attractive, GST key to re rating : BUY January 20, 2018 Amnish Aggarwal amnishaggarwal@plindia.com +91 22 66322233 Nishita Doshi nishitadoshi@plindia.com +91 22 66322381 Rating BUY Price Rs274

More information

Is bet on big data going to be even bigger? Source: Company Data; PL Research

Is bet on big data going to be even bigger? Source: Company Data; PL Research Is bet on big data going to be even bigger? April 23, 2014 Shashi Bhusan shashibhusan@plindia.com +91 22 66322300 Hussain Kagzi hussainkagzi@plindia.com +91 22 66322242 Rating BUY Price Rs531 Target Price

More information

NIIT Technologies. Source: Company Data; PL Research

NIIT Technologies. Source: Company Data; PL Research Humble valuations leads to favourable risk return January 17, 2017 Madhu Babu madhubabu@plindia.com +91 22 66322300 Rating BUY Price Rs416 Target Price Rs520 Implied Upside 25.0% Sensex 27,236 Nifty 8,398

More information

Jindal Steel & Power

Jindal Steel & Power Angul plant s Turnaround, a reality now; Reiterate BUY January 22, 2018 Kamlesh Bagmar kamleshbagmar@plindia.com +91 22 66322237 Amit Khimesra amitkhimesra@plindia.com +91 22 66322244 Rating BUY Price

More information

Crompton Greaves Consumer Electricals

Crompton Greaves Consumer Electricals Enough headroom for growth in core categories February 20, 2018 Kunal Sheth kunalsheth@plindia.com +91 22 66322257 Shreyans Jain shreyansjain@plindia.com +91 22 66322256 Rating BUY Price Rs232 Target Price

More information

Cummins India. Focusing on growth in core segments. Source: Company Data; PL Research

Cummins India. Focusing on growth in core segments. Source: Company Data; PL Research Focusing on growth in core segments June 07, 2018 Kunal Sheth kunalsheth@plindia.com +91 22 66322257 Shreyans Jain shreyansjain@plindia.com +91 22 66322256 Rating BUY Price Rs681 Target Price Rs857 Implied

More information

Sonata Software. Strong growth, reasonable valuations. Source: Company Data; PL Research

Sonata Software. Strong growth, reasonable valuations. Source: Company Data; PL Research Strong growth, reasonable valuations August 16, 2017 Madhu Babu madhubabu@plindia.com +91 22 66322300 Rating BUY Price Rs160 Target Price Rs200 Implied Upside 25.0% Sensex 31,771 Nifty 9,897 (Prices as

More information

S Chand and Company. TP of Rs679 (implying PER of 20x FY19E earnings) Source: Company Data; PL Research

S Chand and Company. TP of Rs679 (implying PER of 20x FY19E earnings) Source: Company Data; PL Research 2Q is a non event, annual guidance remains intact November 20, 2017 Keyur Pandya keyurpandya@plindia.com +912266322247 R Sreesankar rsreesankar@plindia.com +912266322214 Rating BUY Price Rs461 Target Price

More information

Source: Company Data; PL Research

Source: Company Data; PL Research Portfolio realignment to yield benefits in medium term October 22, 2016 Govind Agarwal govindagarwal@plindia.com +91 22 66322300 Rating Accumulate Price Rs499 Target Price Rs600 Implied Upside 20.2% Sensex

More information

Indraprastha Gas. Source: Company Data; PL Research

Indraprastha Gas. Source: Company Data; PL Research MNGL on an accelerated growth trajectory August 29, 2016 Avishek Datta avishekdatta@plindia.com +91 22 66322254 Rating Accumulate Price Rs784 Target Price Rs725 Implied Upside 7.5% Sensex 27,782 Nifty

More information

Dabur India. Source: Company Data; PL Research

Dabur India. Source: Company Data; PL Research Deflation and poor demand impacts sales; Accumulate July 27, 2016 Amnish Aggarwal amnishaggarwal@plindia.com +91 22 66322233 Gaurav Jogani gauravjogani@plindia.com +91 22 66322238 Rating Accumulate Price

More information

NIIT Technologies. Source: Company Data; PL Research

NIIT Technologies. Source: Company Data; PL Research Third Consecutive quarter of strong execution January 20, 2018 Madhu Babu madhubabu@plindia.com +91 22 66322300 Rating BUY Price Rs728 Target Price Rs875 Implied Upside 20.2% Sensex 35,512 Nifty 10,895

More information

Kotak Mahindra Bank. Healthy operating performance. Source: Company Data; PL Research

Kotak Mahindra Bank. Healthy operating performance. Source: Company Data; PL Research Healthy operating performance May 06, 2011 Abhijit Majumder abhijitmajumder@plindia.com +91 22 66322236 Umang Shah umangshah@plindia.com +91 22 66322242 Rating Accumulate Price Rs422 Target Price Rs485

More information

IDEA RESEARCH. Q2FY19 Result Update Tuesday, November 13, Mold Tek Packaging Lower gross margins & higher interest cost impacts profitability

IDEA RESEARCH. Q2FY19 Result Update Tuesday, November 13, Mold Tek Packaging Lower gross margins & higher interest cost impacts profitability (MTEP) reported Q2 results, slightly below expectations. Cons. net sales grew by 27.1% YoY but were marginally lower sequentially to Rs 1,005m. Q2 is a seasonally weak quarter (Q1 and Q4 being stronger).

More information

Tata Motors. Turnaround 2.0, Fit for future; BUY. Source: Company Data; PL Research

Tata Motors. Turnaround 2.0, Fit for future; BUY. Source: Company Data; PL Research Turnaround 2.0, Fit for future; BUY June 06, 2018 Saksham Kaushal sakshamkaushal@plindia.com +91 22 66322235 Poorvi Banka poorvibanka@plindia.com +91 22 66322426 Rating BUY Price Rs296 Target Price Rs378

More information

Dabur India. Steady recovery in place; Accumulate. Source: Company Data; PL Research

Dabur India. Steady recovery in place; Accumulate. Source: Company Data; PL Research Steady recovery in place; Accumulate January 31, 2018 Amnish Aggarwal amnishaggarwal@plindia.com +91 22 66322233 Nishita Doshi nishitadoshi@plindia.com +91 22 66322381 Rating Accumulate Price Rs354 Target

More information

Dabur India. Share gains power growth, Accumulate. Source: Company Data; PL Research

Dabur India. Share gains power growth, Accumulate. Source: Company Data; PL Research Share gains power growth, Accumulate May 02, 2018 Amnish Aggarwal amnishaggarwal@plindia.com +91 22 66322233 Nishita Doshi nishitadoshi@plindia.com +91 22 66322381 Rating Accumulate Price Rs371 Target

More information

Crompton Greaves Consumer Electricals (CROMPTON IN) Rating: BUY CMP: Rs195 TP: Rs276

Crompton Greaves Consumer Electricals (CROMPTON IN) Rating: BUY CMP: Rs195 TP: Rs276 Crompton Greaves Consumer Electricals (CROMPTON IN) Rating: BUY CMP: Rs195 TP: Rs276 October 26, 2018 Q2FY19 Result Update Change in Estimates Target Reco Change in Estimates Current Previous FY19E FY20E

More information

VRL Logistics. Steady show in tough environment. Source: Company Data; PL Research

VRL Logistics. Steady show in tough environment. Source: Company Data; PL Research Steady show in tough environment November 05, 2017 Keyur Pandya keyurpandya@plindia.com +91 22 66322247 R Sreesankar rsreesankar@plindia.com +91 22 66322214 Rating Accumulate Price Rs376 Target Price Rs370

More information